
This article was downloaded by:

On: 29 January 2011

Access details: Access Details: Free Access

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Phosphorus, Sulfur, and Silicon and the Related Elements

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713618290

SYNTHESIS AND APPLICATION OF SOME NEW 5-SULPHONYL-N-HETEROCYCLO-8-HYDROXYQUINOLINE DERIVATIVES AS POTENTIAL DRUGS

Ali A. Abdel Hafeza; Ibrahim M. A. Awada

^a Chemistry Department, Faculty of Science, Assiut University, Assiut, Egypt

To cite this Article Hafez, Ali A. Abdel and Awad, Ibrahim M. A.(1991) 'SYNTHESIS AND APPLICATION OF SOME NEW 5-SULPHONYL-N-HETEROCYCLO-8-HYDROXYQUINOLINE DERIVATIVES AS POTENTIAL DRUGS', Phosphorus, Sulfur, and Silicon and the Related Elements, 61: 3, 381 — 389

To link to this Article: DOI: 10.1080/10426509108036821 URL: http://dx.doi.org/10.1080/10426509108036821

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

Communication

SYNTHESIS AND APPLICATION OF SOME NEW 5-SULPHONYL-N-HETEROCYCLO-8-HYDROXYQUINOLINE DERIVATIVES AS POTENTIAL DRUGS

ALI A. ABDEL HAFEZ and IBRAHIM M. A. AWAD† Chemistry Department, Faculty of Science, Assiut University, Assiut-Egypt

(Received January 18, 1990; in final form June 15, 1990)

Some new sulphonyl-N-heterocyclo-8-hydroxy quinolines have been synthesised by the reaction of 8hydroxyquinoline-5-sulphonyl hydrazide with different active methylene compounds. The pyrazole, pyrazoline, pyrazolidine and pyridazine derivatives were reacted with some metal cations to give the corresponding chelates. All synthesized compounds have been screened in vitro for their biological activities.

Key words: Synthesis, 5-sulphonyl-8-Hydroxyquinoline derivatives; N-sulphonyl pyrazolines; their chelates and biological screening.

INTRODUCTION

A literature survey has revealed that the sulphonamide derivatives have been found to be biologically important compounds having anticancer, antimalaria, antitubercular, and other activities. 1-5 Some of the 8-hydroxyquinoline derivatives and their complexes with transition metals were reported to be active against bacteria.⁶ In view of this biological significance, we wish to report an investigation concerning the synthesis of some new N-[5-sulphonyl-8-hydroxyquinoline]pyrazole derivatives and their complexes to test the change in antimicrobial activities of these ligands on chelation.

RESULTS AND DISCUSSIONS

Extensive efforts have been done to prepare new members of pyrazolines⁷⁻¹⁴ for their wide application in different fields, but these containing 5-sulphonyl 8-hydroxyquinoline moiety were not mentioned before. In this work 5-sulphonylheterocyclo-8-hydroxyquinoline were prepared, to evaluate the effect of substitution on the microbial activity of the 8-hydroxyquinoline nucleus.

A series of 5-sulphonyl-N-heterocyclo-8-hydroxyquinoline (1_a-5_a) has been synthesized by condensation of 8-hydroxyquinoline-5-sulphonyl hydrazide¹⁵ with active

[†] Author to whom correspondence should be addressed.

methylene compounds e.g. ethyl cyanoacetate, ethyl acetoacetate, acetyl acetone, diethyl malonate and malononitrile.

Also, on treatment of 8-hydroxyquinoline-5-sulphonyl hydrazide with 2,4-pentanediole and/or dimethyl succinate in presence of fused sodium acetate for 45–60 minutes gave (6_a) and (7_a) compounds, respectively (Scheme I).

Scheme I

TABLE I

Analysis and physical properties of the synthesized compounds $1_{a-d}-7_{a-d}$

ompound	mp.	Yield	Formula		% Calc	d.		% Foun	d
No.	°C	%	rormula	С	н	S	С	Н	S
la	312	70	C ₁₂ H ₁₀ N ₄ O ₄ S	47.06	3.27	10.46	47.10	3,26	10.4
b	> 300	80	Fe(C ₁₂ H ₁₀ N ₄ O ₄ S) ₂ NO ₃	39.46	2.74	8.77	39.44	2.76	8.7
c	> 300	78	Cu(C ₁₂ H ₁₀ N ₄ O ₄ S) ₂	42.63	2.96	9.47	42.60	2.97	9.4
d	289	82	Hg(C ₁₂ H ₁₀ N ₄ O ₄ S) ₂	35.44	2.46	7.88	35.46	2.44	7.8
2a	287	78	C ₁₃ H ₁₁ N ₃ O ₄ S	51.15	3.61	10.49	51.17	3.60	10.4
b	258	84	Fe(C ₁₃ H ₁₁ N ₃ O ₄ S) ₂ NO ₃	42.87	3.02	8.79	42.86	3.05	8.7
С	270	69	Cu(C ₁₃ H ₁₁ N ₃ O ₄ S) ₂	46.32	3.27	9.50	46.34	3.25	9.5
d	250	77	Hg(C ₁₃ H ₁₁ N ₃ O ₄ S) ₂	38.49	2.71	7.90	38.48	2.73	7.9
3a	285	80	C14H13N3O3S	55.45	4.29	10.56	55.49	4.30	۱۲ ۰
b	305	87	Fe(C ₁₄ H ₁₃ N ₃ O ₃ S) ₂ NO ₃	46.42	3.59	8.84	46.41	3.56	.80
c	330	78	Cu(C14H13N303S)2	50.18	3.88	9.56	50.20	3.86	9.5
d	290	88	Hg(C ₁₄ H ₁₃ N ₃ O ₃ S) ₂	41.66	3.22	7.94	41.68	3.24	7.90
4a	297	67	C ₁₂ H ₉ N ₃ O ₅ S	46.91	2.93	10.42	46.90	2.92	10.46
b	308	70	Fe(C ₁₂ H ₉ N ₃ O ₅ S) ₂ NO ₃	39.35	2.46	8.46	39.38	2.47	8.79
c	> 300	58	Cu(C12H9N305S)2	42.51	2.66	9.46	42.52	2.67	9.48
d	282	70	Hg(C12H9N305S)2	35.36	2.21	7.86	33.38	2.20	7.84
5a	273	71	C ₁₂ H ₁₁ N ₅ O ₃ S	47.21	3.61	10.49	47.22	3.60	10.48
b :	> 300	68	Fe(C ₁₂ H ₁₁ N ₅ 0 ₃ S) ₂ NO ₃	39.57	3.02	8.79	39.59	3.00	8.77
c :	> 300	60	Cu(C12H11N503S)2	42.76	3.27	9.50	42.79	3.26	9.49
d	305	74	Hg(C ₁₂ H ₁₁ N ₅ 0 ₃ S) ₂	35.53	2.71	7.90	35.60	2.70	7.88
6a	175	62	C14H16N3O3S	54.89	5.26	10.47	54.90	5.23	10.66
b :	> 300	78	Fe(C14H16N3O3S)2NO3	45.98	4.40	8.64	46.00	4.42	8.60
c >	300	69	Cu(C14H16N3O3S)2	49.68	4.76	9.40	49.70	4.77	9.69
d	278	80	Hg(C14H16N3O3S)2	41.31	3.95	7.69	41.40	3.98	7.90
7a	302	65	C13H11N3O5S	47.13	3.32	9.67	47.15	3.30	9.66
b	310	71	Fe(C ₁₃ H ₁₁ N ₃ O ₅ S) ₂ NO ₃	40.01	2.82	8.21	40.00	2.83	8.22
С	320	60	Cu(C13H11N3O5S)2	43.00	3.03	8.82	42.88	3.05	8.84
d	290	78	Hg(C ₁₃ H ₁₁ N ₃ O ₅ S) ₂	36.17	2.55	7.42	36.19	2.53	7.44

TABLE II
Important IR bands of synthesized compounds 1_a-7_a (ligands) cm⁻¹

Assignment	l _a	2 a	3 _a	4 _a	5 _a	6 _a	7 _a
ν0H	3180	3145	3175	3165	3160	3190	3180
ν _{asym} .S±0	1320	1325	1320	1330	1325	1330	1333
ν _{sym} . S=0	1160	1150	1145	1155	1160	1150	1160
νNH	-	-	-	3280	3210	3260	3280
vNH ₂	3310	1	-	-	3320	-	-
∨C=0	1760	1760	-	1775	-	-	1775
monocyclic							
=========	======	=======				========	======

TABLE III
Important IR bands of metal chelates $(1_{b-d}-7_{b-d})$ cm⁻¹

Assignment	1 b - d	2 b - d	3 b - d	⁴ b-d	⁵ b - d	6 _{b-d}	⁷ b-d
νOH	-	-	-	_	-	-	_
v _{asym} .S=0	1340	1330	1335	1340	1325	1340	1335
$v_{sym}.S=0$	1150	1165	1170	1140	1145	1170	1165
NH	-	-	-	3260	3220	3250	3260
νNH ₂	3320	_	-	-	3330	-	-
∨ C = 0	1750	1755	-	1745	-	-	1750
Vasym. ^{NO}	1260	1265	1290	1265	1280	1285	1280
v _{sym} .NO	1030	1025	1030	1035	1020	1025	1030
ν M-0	350	345	340	390	355	360	370

TABLE IV

1H-NMR spectra of the synthesized compounds (Chemical shifts in 8ppm)

Compound	Aromatic	-0H	
No.	protons (m, 5H)	(s, 1H)	
l _a	7.80-7.20	9.01	65.50(s, 2H, NH ₂), 64.30(s, 2H, CH ₂ -
1 b,c,d	7.90-7.00	-	pyrazolyl ring).
2 _a	7.80-7.10	9.02	$\delta 2.20$ (s, $3H$, CH_3 of pyrazole ring),
² b,c,d	8.00-7.20	-	64.20 (s, 2H, CH ₂ pyrazolyl ring).
3 _a	8.00-7.10	9.00	62.40-2.10 (t, 6H, 2 CH ₃ of pyrazol
3 _{b,c,d}	7.80-7.00	-	ring), $\delta 7.76$ (s, CH pyrazolyl ring).
4 a	7.90-7.10	8.90	δ3.70 (s, 1H, NH), δ4.20 (s, 2H,
⁴ b,c,d	8.00-7.00	-	CH ₂ pyrazolyl ring).
5 _a	7.70-7.20	9.00	δ 4.20 (s, 2H, CH ₂ pyrazolyl ring),
⁵ b,c,d	7.90-7.30	-	δ3.40 (s, 1H, NH), δ5.50 (s, 2H, NH ₂).
6 a	7.60-7.20	8.92	δ3.50 (s, 1H, NH), δ4.50-4.00 (s, 2H,
⁶ b,c,d	7.80-7.10	-	CH ₂ of pyrazolyl ring), 82.50-2.15
			(t, 6H, 2CH ₃ of pyrazole ring).
7 _a	7.60-7.10	8.94	δ4.40-4.10 (d, 4H, 2 CH ₂ of diazine
⁷ h,c,d	7.90-7.20	-	ring, 63.50 (s, 1H, NH).

The structures of the synthesised compounds were confirmed on the basis of microanalytical data, ${}^{1}H$ -NMR and IR spectroscopic evidence (Tables I, II, III and IV). Complexation of the ligand $(\mathbf{1_a}-\mathbf{7_a})$ was carried out by refluxing an ethanolic solution of 5-sulphonyl-N-heterocyclo-8-hydroxyquinoline $\mathbf{1_a}-\mathbf{7_a}$ with metal salts at $50-60^{\circ}\mathrm{C}$, to give $\mathbf{1_{b-d}}-\mathbf{7_{b-d}}$ compounds, respectively (Scheme II).

The overall study and the analytical data (Table I) shows that all compounds form chelates of the type ML_2 where L= ligand. The IR spectra of ligands shows bands at 3 100 cm⁻¹ and 3 150-3 050 cm⁻¹. Instead, these bands are located at 370-340 cm⁻¹ in the corresponding chelates due to the involvement of —OH group of quinoline in chelate formation. The bands around 1 600 cm⁻¹ in the spectra of ligands due to ν shift to lower values with weak intensity

Downloaded At: 15:39 29 January 2011

TABLE V
Antibacterial screening of compounds I_{a-d}-7_{a-d} (inhibition zones mm)

		, mineral management		compoduras .	IOIIIII) P-e, P-e	(IIIII) COHOZ HOHIOHHHI P-e, _P-e, _P-e, _DHI COHOZ GILLION TO GIL		
Compound	Formula	Bacillus	Serratia	Bacillus	Pesudomonas	Escherichio	Micrococcus	Staphylococcus
No.		cereus	sp.	subtilis	aeruginosa	coli	roseus	aureus
la	C12H10N404S	20	15	20	10	15	10	25
Q	$Fe(C_{12}H_{10}N_40_4S)_2N0_3$	-ve	· <e< td=""><td>10</td><td>10</td><td>30</td><td>10</td><td>15</td></e<>	10	10	30	10	15
v	Cu(C ₁₂ H ₁₀ N ₄ O ₄ S) ₂	30	20	e >	10	30	30	04
Ð	$^{Hg}(c_{12}^{H_{10}}^{H_{10}}^{N_{4}}^{O_{4}}^{S})_{2}$	09	20	80	09	09	09	90
2a	C13H11N3O4S	35	20	25	30	10	20	25
۵	Fe(C ₁₃ H ₁₁ N ₃ O ₄ S) ₂ NO ₃	25	- < 6	· ve	0 †	10	1.5	20
ပ	Cu(C ₁₃ H ₁₁ N ₃ 0 ₄ S) ₂	20	10	· ve	0 †	15	15	30
ס	Hg(C ₁₃ H ₁₁ N ₃ O ₄ S) ₂	09	50	90	20	09	20	80
За	C14H13N3O3S	20	30	20	50	20	09	0+
q	Fe(C ₁₄ H ₁₃ N ₃ O ₃ S) ₂ NO ₃	4.0	20	e > -	10	80	- ve	1.5
o	Cu(C ₁₄ H ₁₃ N ₃ O ₃ S) ₂	45	10	15	40	10	20	30
Ð	Hg(C ₁₄ H ₁₃ N ₃ O ₃ S) ₂	80	90	7.5	80	80	09	85
ф а	C12H9N3O5S	0 †	20	0 †	40	0 †	4.5	50
٩	Fe(C ₁₂ H ₉ N ₃ O ₅ S) ₂ NO ₃	20	10	e .	15	15	- < 6	50
ပ	Cu(C ₁₂ H ₉ N ₃ O ₅ S) ₂	15	-ve	20	04	20	e .	15
ъ	Hg(C ₁₂ H ₉ N ₃ 0 ₅ S) ₂	80	09	70	20	09	45	7.5

in the spectra of chelates due to $M \leftarrow N$ bond formation (Table III).

The bacteriostatic activities of the synthesized compounds $\mathbf{I_{a-d}}$ to $\mathbf{7_{a-d}}$ showed variable effects (inhibition zones ranged from 10 to 90 mm) against bacteria used (Table V). Whears compounds from $\mathbf{I_d}$ to $\mathbf{7_d}$ showed high potential activities (inhibition zones ranged from 50 to 90 mm) against all bacteria used. Furthermore, all of tehse compounds showed mild and strong activities (inhibition zones ranged from 10 to 90 mm) against Bacillus cereus, Pesudomonas aeruginosa, Escherichia coli and Staphylococcus aureus. Interestingly, compounds from $\mathbf{I_a}$ to $\mathbf{7_a}$ as ligands showed mild and strong activities (inhibition zones from 10 to 75 mm) against all of the bacteria used.

EXPERIMENTAL

All melting points are uncorrected. Microanalysis were done at the Department of Chemistry, Faculty of Science, Assiut University. IR spectra were rune on a Pye Unicam sp 200 G spectrophotometer in KBr discs. 'H-NMR spectra were done on a EOL-FT 270 MHz NMR Instrument using TMS as an internal standard.

Synthesis of 5-sulphonyl-N-heterocyclo-8-hydroxyquinolines (1_a-7_a) .

General procedure: A mixture of 8-hydroxyquinoline-5-sulphonyl hydrazide (A) (2.08 g, 0.01 mole), was reacted with active methylene compounds (equal molar ratio) e.g. ethyl cyanoacetate, ethyl acetoacetate, acetyl acetone, diethyl malonate, malononitrile, 2,4-pentanediol and dimethyl succinate in presence of fused sodium acetate (0.7 g) by fusion on an oil bath at 200-220°C for 20-30 minutes, then refluxed with 10 ml absolute ethanol for 2-4 hours. The reaction mixture was poured into ice water and stirred for 1 hour. The solid thus obtained was collected and crystallized from the proper solvent (Table I) gave the following synthesized compounds listed as follows:

N-(5-Sulphonyl-8-hydroxyquinoline)-3-amino-2-pyrazoline-5-one ($\mathbf{1}_a$); N-(5-Sulphonyl-8-hydroxyquinoline)-3-methyl-2-pyrazoline-5-one ($\mathbf{2}_a$); N-(5-Sulphonyl-8-hydroxyquinoline)-3,5-dimethylpyrazole ($\mathbf{3}_a$); N-(5-Sulphonyl-8-hydroxyquinoline)-N-2-(\mathbf{H})-pyrazolidine-3,5-dione ($\mathbf{4}_a$); N-(5-Sulphonyl-8-hydroxyquinoline)-3,5-dimethyl-N-2-(\mathbf{H})-pyrazolidine ($\mathbf{5}_a$); N-(5-Sulphonyl-8-hydroxyquinoline)-3,5-dimethyl-N-2-(\mathbf{H})-pyrazolidine ($\mathbf{5}_a$); and N-(5-sulphonyl-8-hydroxyquinoline)-N-2-(\mathbf{H})-4,5-dihydro pyridazine-3,6-dione ($\mathbf{7}_a$), respectively.

Preparation of the complexes: A hot ethanolic solution of an appropriate amount of the ligand was mixed at continuous stirring with a calculated amount of the respective metal salt (ferric nitrate, copper acetate and mercuric chloride) suspended in ethyl alcohol in the molar ratio 2:1; precipitation of the complex occurs immediately. The product was filtered, washed with little alcohol and dried.

Screening for biological activity: The antibacterial activities of all synthesized compounds $\mathbf{1}_{\mathbf{a}-\mathbf{d}}$ to $\mathbf{7}_{\mathbf{a}-\mathbf{d}}$ have been studied and screened in vitro against Gram-positive and Gram-negative bacteria used namely: Bacillus cereus, Serratia sp., Bacillus subtilis, Pesudomonas aeruginosa, Escherichia coli, Micrococcus roseus and Staphylococcus aureus.

The bacteriostatic activities were tested by the usual cup plate agar diffusion technique, $^{18.19}$ 1% dimethyl formamide solution of the chelates were prepared. The dishes were allowed to stand in a refrigerator at 4-8°C for 0.5 hr. to allow diffusion of the solutions and were incubated at 37 \pm 1°C for 48 hr. The inhibition zones were measured with the callipers.

REFERENCES

- 1. E. Profft and G. Buchmann, Arzneimittel Forsch, 10, 181 (1960).
- 2. H. Nishihara, J. Biol. Chem. Japan 40, 579 (1953).
- 3. J. A. Vaichulis, U. S. Patent, 3,271,251 (1966); C.A. 65, 19938° (1966).
- 4. L. H. Schmidt, Ann. Rev. Microbiol, 23, 427 (1969).
- 5. G. Tarbini, Int. Cong. Chemotherapy, Proc., 5th (2), 909 (1967).
- 6. G. D. Tiwari and M. N. Mishra, J. Indian Chem. Soc., LIX, 362 (1982).

- 7. L. Raiford and H. Davis, J. Amer. Chem. Soc., 50, 156 (1928).
- 8. R. Lacouir and R. Hailman, Bull. Chem. Soc., 45, 541 (1929).
- 9. L. Raiford and G. Gundy, J. Org. Chem., 3, 265 (1933).
- 10. S. G. Beech, J. H. Turnbull and W. Wilson, J. Chem. Soc., 4686 (1962).
- A. Sammour, M. I. Selim and G. H. Elsayed, Egypt. J. Chem., 14, 235 (1971); C.A. 77, 139878^a (1972).
- 12. A. Sammour, A. Marei and M. H. Hussein, Egypt. J. Chem., 12, 461 (1969).
- 13. A. Sammour and M. El Kasaby, Egypt. J. Chem., 13, 248 (1970).
- 14. A. M. Osman, Kh. M. Hassan and M. A. El Maghraby, Ind. J. Chem., 14B, 282 (1976).
- 15. A. A. Abdel Hafez, I. M. A. Awad and Kh. M. Hassan, Phosphorus and Sulfur, 40, 219 (1988).
- 16. L. J. Bellamy, The Infrared Spectra of Complex Molecules (London) 1952.
- 17. L. P. Garrod and F. G. Grady, Antibiotics and Chemotherapy, 3rd ed., Churchill Livingston, Edinburgh and London, p. 477 (1972).
- 18. British Pharmacopacia, Pharmaceutical Press, London, 796 (1953).